Thermo Fisher Scientific Inc.: Form 10-K for the period ended Dec 31, 2017
Filed with the SEC on Feb 28, 2018 and accepted by EDGAR at Feb 28, 2018, 09:19 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2017-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Cost of revenue | 12 months2017-01-01 to 2017-12-31 | $8.98bn | us-gaap:CostOfGoodsSold |
| Gross profit | 3 months2017-10-01 to 2017-12-31 | $2.67bn | us-gaap:GrossProfit |
| Research and development | 12 months2017-01-01 to 2017-12-31 | $888.0m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 12 months2017-01-01 to 2017-12-31 | $5.49bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 12 months2017-01-01 to 2017-12-31 | $2.97bn | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months2017-01-01 to 2017-12-31 | $592.0m | us-gaap:InterestExpense |
| Income tax | 12 months2017-01-01 to 2017-12-31 | $201.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2017-10-01 to 2017-12-31 | $528.0m | us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic |
| Net income | 12 months2017-01-01 to 2017-12-31 | $2.23bn | us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic |
| Diluted EPS | 3 months2017-10-01 to 2017-12-31 | $1.30 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 12 months2017-01-01 to 2017-12-31 | $5.59 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2017-10-01 to 2017-12-31 | $1.32 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 12 months2017-01-01 to 2017-12-31 | $5.64 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2017-01-01 to 2017-12-31 | 398,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2017-01-01 to 2017-12-31 | $4.00bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2017-01-01 to 2017-12-31 | $508.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 12 months2017-01-01 to 2017-12-31 | $237.0m | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 12 months2017-01-01 to 2017-12-31 | $750.0m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2017-12-31 | $1.33bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2017-12-31 | $9.42bn | us-gaap:AssetsCurrent |
| Total assets | At period end2017-12-31 | $56.67bn | us-gaap:Assets |
| Current liabilities | At period end2017-12-31 | $7.05bn | us-gaap:LiabilitiesCurrent |
| Current portion of debt | At period end2017-12-31 | $2.13bn | us-gaap:DebtCurrent |
| Short-term borrowings | At period end2017-12-31 | $960.0m | us-gaap:ShortTermBorrowings |
| Shareholders' equity | At period end2017-12-31 | $25.41bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000097745-18-000006. Last ingested by Listed: Nov 14, 2026, 12:05 ET. Listed shows no prices and gives no investment advice.